Clinical Trial Update: Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell. [Phase 1, Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 1/2 clinical trial evaluating sequential infusion of allogeneic mesenchymal stem cells to treat refractory graft-v…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Allogeneic mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: Grupo Espanol de trasplantes hematopoyeticos y terapia celular | Conditions: Chronic Graft-Versus-Host Disease | Phase 1, Phase 2 | Status: COMPLETED